The landscape of HIV treatment is on the precipice of a significant transformation. At the 26th International AIDS Conference, pharmaceutical giants Gilead Sciences and Merck presented pivotal Phase 3 data that could fundamentally alter how clinicians and patients manage HIV. The investigational oral combination of islatravir (2 mg) and lenacapavir (300 mg)—a once-weekly tablet—demonstrated robust virologic suppression in two major clinical trials, ISLEND-1 and ISLEND-2, involving over 1,200 participants.
If granted regulatory approval, this regimen would mark a historic milestone: the first once-weekly oral maintenance treatment for adults living with HIV. By shifting from daily adherence to a weekly dosing schedule, Gilead and Merck aim to reduce the psychological and physical burden of treatment for millions, potentially setting a new standard in a market currently dominated by high-performing, once-daily single-tablet regimens.
Main Facts: The Efficacy of Weekly Dosing
The core promise of the islatravir/lenacapavir (ISL/LEN) combination lies in its pharmacokinetic profile. Islatravir, Merck’s next-generation nucleoside reverse transcriptase translocation inhibitor (NRTTI), acts as a potent antiretroviral. When paired with Gilead’s lenacapavir—the first-in-class capsid inhibitor already marketed as Sunlenca—the combination achieves a half-life long enough to support weekly oral dosing without sacrificing efficacy.
In the ISLEND-1 and ISLEND-2 trials, which concluded their 48-week primary endpoints with overwhelming success, the primary objective was to maintain viral suppression (HIV-1 RNA < 50 copies/mL) in patients who were already stable on their current antiretroviral therapy (ART). The results confirmed that switching to the weekly pill was non-inferior to continuing daily standard-of-care regimens, most notably the market-leading Biktarvy.
Chronology of Development
The road to this breakthrough has been a methodical, multi-year endeavor marked by both rapid innovation and cautious clinical oversight.
- October 2024: Gilead and Merck announced promising Phase 2 data. A study of 104 virologically suppressed adults showed that 94.2% of those on the weekly regimen maintained suppression at Week 48, with zero participants showing viral rebound at or above 50 copies/mL.
- November 2024: During the HIV Glasgow conference, clinical investigators addressed the nuance of "hepatitis B coverage." Because the proposed ISL/LEN regimen does not contain tenofovir—a component of many current regimens that acts against both HIV and HBV—the scientific community began emphasizing the need for robust hepatitis B immunization protocols as part of the clinical pathway.
- April 2026: The FDA signaled confidence in the underlying chemistry by approving Merck’s Idvynso (doravirine/islatravir), validating islatravir as a safe and effective component of modern HIV therapy.
- June 2026: Gilead and Merck released topline findings from the ISLEND Phase 3 trials, confirming that the combination met all primary efficacy endpoints.
- July 2026: Detailed results were presented at the 26th International AIDS Conference, providing the medical community with the granular safety and efficacy data needed to evaluate the regimen’s future in clinical practice.
Supporting Data: Examining the Trials
The clinical rigor behind ISLEND-1 and ISLEND-2 provides a comprehensive picture of how this regimen performs under different clinical environments.
ISLEND-1: The Double-Blind Benchmark
ISLEND-1 utilized a double-blind design to compare the weekly ISL/LEN combination directly against Biktarvy (the gold standard of daily oral treatment). The results were striking: zero participants in the investigational arm experienced viral failure (HIV-1 RNA ≥ 50 copies/mL) at Week 48, compared to 0.3% in the Biktarvy group. Safety profiles remained largely comparable; treatment-related adverse events (TRAEs) were 13.5% for ISL/LEN and 13.2% for the control group. Nausea and headache were the most commonly reported side effects, occurring in roughly 3% of the investigational group.
ISLEND-2: Real-World Flexibility
ISLEND-2, an open-label trial, provided a more pragmatic assessment by allowing patients to switch from a variety of existing two- and three-drug regimens. Despite the more diverse baseline, the efficacy remained exceptionally high. Only 0.3% of ISL/LEN participants had HIV-1 RNA at or above 50 copies/mL at Week 48. While TRAEs were reported at a higher rate in the ISL/LEN group (18% vs. <1%), researchers noted this was likely a result of the trial design: participants on standard-of-care regimens had already been stable for months, effectively bypassing the "acclimation" period where side effects are most likely to occur. Crucially, discontinuation rates due to adverse events remained low (2% and 1.7% respectively).
Patient Perspectives and Quality of Life
Beyond laboratory metrics, the human element of the trial underscored the potential for improved quality of life. In ISLEND-2, participants utilizing the HIV Patient Perspective of Regimen Change instrument reported significantly higher satisfaction scores compared to their previous daily regimens. Patients frequently described the transition to a once-weekly pill as "less burdensome," a sentiment that could lead to improved long-term adherence in a real-world setting where "pill fatigue" is a known clinical challenge.
Implications for the HIV Treatment Market
The financial and strategic stakes of this development are immense. The HIV treatment market is currently defined by the massive commercial footprint of Biktarvy, which generated $14.3 billion in 2025 and accounted for nearly 70% of Gilead’s HIV franchise. Gilead’s decision to pursue a weekly oral successor represents a calculated "cannibalization" strategy—moving patients from a high-earning daily drug to a novel weekly one to stay ahead of competitors and evolving patient needs.
Competitive Pressures
Gilead faces pressure from both sides:
- Injectables: ViiV Healthcare (GSK) has made significant inroads with Cabenuva, an injectable regimen administered every two months. With a 42% growth in 2025, Cabenuva has set the bar for "reduced-frequency" dosing. Gilead’s ISL/LEN provides a unique middle ground: it offers the convenience of reduced frequency without the need for clinical visits or injections, allowing patients to maintain their treatment at home.
- Internal Innovation: Gilead is simultaneously advancing a daily oral bictegravir/lenacapavir regimen (tested in the ARTISTRY trials), ensuring that they have multiple avenues to defend their market share regardless of whether patients prefer daily or weekly dosing.
Clinical Considerations for Practitioners
As the medical community prepares for a potential rollout, clinicians must consider the transition protocols. The absence of tenofovir in the ISL/LEN regimen means that practitioners will need to implement systematic hepatitis B screening and vaccination programs for patients looking to switch. This shift represents a change in standard clinical workflow, requiring education and proactive patient management.
Conclusion: A New Horizon
The success of the islatravir and lenacapavir regimen is more than a win for Gilead and Merck—it is a win for the HIV community. By decoupling HIV management from the daily "reminder" of an oral pill, this combination promises to foster a more discreet, manageable, and patient-centered treatment experience. As Gilead moves toward regulatory filings, the focus will now shift to manufacturing, pricing, and the implementation of educational programs to ensure that the transition to once-weekly dosing is as seamless as the data suggests.
In an era where long-term management of chronic conditions is defined by the quality of life as much as the suppression of disease, the ISL/LEN regimen stands as a testament to the ongoing evolution of antiretroviral therapy. If the positive trend continues, the industry may soon witness the transition from the daily era of HIV treatment to a new, more flexible weekly standard.
About the Author
